APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Sep 19, 2022

Keywords

ClinConnect Summary

The APOLLO 11 clinical trial is focused on improving how lung cancer is treated in Italy by collecting real-world data from around 48 medical centers across the country. Researchers want to build a long-lasting network that helps understand the effectiveness of innovative therapies, such as immune therapies and targeted treatments, which aim to attack cancer cells more precisely. By creating a national database and a biobank—where samples can be stored and studied—they hope to enhance future treatments and research for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of lung cancer that has been treated or is being treated with newer therapies. Unfortunately, patients receiving certain unapproved treatments or only local therapies like surgery or standard chemotherapy before 2010 are not eligible. If you join the trial, you can expect to provide your consent and share some health information, contributing to a significant effort that may help improve lung cancer care for everyone in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;
• • 2. Patients must be ≥18 years of age at the time of signing the informed consent;
• • 3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).
• Exclusion Criteria:
• • 1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.
• • 2. Patients who have not received an oncological systemic innovative therapy at any setting
• • 3. Patients received only local treatments (e.g., only surgery, or only radiotherapy)
• • 4. Patients who received only standard chemotherapy are excluded.
• • 5. Patients who received treatment therapies before 2010 are excluded.